Ginwa Enterprise Group Inc
Ginwa Enterprise (Group) Inc. researches, develops, produces, markets, and sells traditional Chinese medicines, biological drugs, and chemical drugs primarily in China. The company offers a range of orthopaedics, immunity, children, and general medicines in various dosage forms, including tablets, capsules, granules, powders, mixtures, oral solutions, syrups, and external solutions. It is also in… Read more
Ginwa Enterprise Group Inc (600080) - Net Assets
Latest net assets as of September 2025: CN¥1.58 Billion CNY
Based on the latest financial reports, Ginwa Enterprise Group Inc (600080) has net assets worth CN¥1.58 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.96 Billion) and total liabilities (CN¥373.61 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.58 Billion |
| % of Total Assets | 80.91% |
| Annual Growth Rate | 17.6% |
| 5-Year Change | -9.4% |
| 10-Year Change | 49.1% |
| Growth Volatility | 85.93 |
Ginwa Enterprise Group Inc - Net Assets Trend (1994–2024)
This chart illustrates how Ginwa Enterprise Group Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ginwa Enterprise Group Inc (1994–2024)
The table below shows the annual net assets of Ginwa Enterprise Group Inc from 1994 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.56 Billion | -4.82% |
| 2023-12-31 | CN¥1.64 Billion | -2.69% |
| 2022-12-31 | CN¥1.68 Billion | +1.66% |
| 2021-12-31 | CN¥1.66 Billion | -3.78% |
| 2020-12-31 | CN¥1.72 Billion | +0.33% |
| 2019-12-31 | CN¥1.72 Billion | -3.15% |
| 2018-12-31 | CN¥1.77 Billion | +58.39% |
| 2017-12-31 | CN¥1.12 Billion | +4.16% |
| 2016-12-31 | CN¥1.07 Billion | +2.66% |
| 2015-12-31 | CN¥1.05 Billion | +2.52% |
| 2014-12-31 | CN¥1.02 Billion | +2.19% |
| 2013-12-31 | CN¥998.35 Million | +3.76% |
| 2012-12-31 | CN¥962.22 Million | +4.77% |
| 2011-12-31 | CN¥918.45 Million | +26.69% |
| 2010-12-31 | CN¥724.97 Million | +4.83% |
| 2009-12-31 | CN¥691.57 Million | -0.67% |
| 2008-12-31 | CN¥696.22 Million | -6.81% |
| 2007-12-31 | CN¥747.13 Million | +6.34% |
| 2006-12-31 | CN¥702.59 Million | -10.05% |
| 2005-12-31 | CN¥781.05 Million | -11.35% |
| 2004-12-31 | CN¥881.06 Million | +1.29% |
| 2003-12-31 | CN¥869.84 Million | +2.24% |
| 2002-12-31 | CN¥850.75 Million | +2.53% |
| 2001-12-31 | CN¥829.75 Million | +5.04% |
| 2000-12-31 | CN¥789.96 Million | +64.24% |
| 1999-12-31 | CN¥480.99 Million | +19.90% |
| 1998-12-31 | CN¥401.15 Million | +33.83% |
| 1997-12-31 | CN¥299.75 Million | +341.10% |
| 1996-12-31 | CN¥67.96 Million | +349.95% |
| 1995-12-31 | CN¥15.10 Million | +25.54% |
| 1994-12-31 | CN¥12.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ginwa Enterprise Group Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 50343.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥512.11 Million | 32.82% |
| Common Stock | CN¥373.27 Million | 23.92% |
| Other Comprehensive Income | CN¥61.45 Million | 3.94% |
| Other Components | CN¥613.67 Million | 39.33% |
| Total Equity | CN¥1.56 Billion | 100.00% |
Ginwa Enterprise Group Inc Competitors by Market Cap
The table below lists competitors of Ginwa Enterprise Group Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MARAVAI LIFESC.HLD.A -01
F:MAR
|
$264.39 Million |
|
Jiangsu Feymer Technology Co Ltd
SHG:688350
|
$264.42 Million |
|
PYC Therapeutics Ltd
AU:PYC
|
$264.67 Million |
|
B.Grimm Power Public Company Limited
BK:BGRIM
|
$264.68 Million |
|
Qingdao NovelBeam Technology Co. Ltd. A
SHG:688677
|
$264.14 Million |
|
Guangdong Huiyun Titanium Industry
SHE:300891
|
$264.10 Million |
|
Moso Power Supply Technology Co Ltd
SHE:002660
|
$264.10 Million |
|
US Century Bank
NASDAQ:USCB
|
$264.06 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ginwa Enterprise Group Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,638,426,525 to 1,560,494,557, a change of -77,931,968 (-4.8%).
- Net income of 74,611,329 contributed positively to equity growth.
- Dividend payments of 3,306,434 reduced retained earnings.
- Share repurchases of 149,501,191 reduced equity.
- Other comprehensive income increased equity by 186,991,511.
- Other factors decreased equity by 186,727,183.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥74.61 Million | +4.78% |
| Dividends Paid | CN¥3.31 Million | -0.21% |
| Share Repurchases | CN¥149.50 Million | -9.58% |
| Other Comprehensive Income | CN¥186.99 Million | +11.98% |
| Other Changes | CN¥-186.73 Million | -11.97% |
| Total Change | CN¥- | -4.76% |
Book Value vs Market Value Analysis
This analysis compares Ginwa Enterprise Group Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.97x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 218.26x to 1.97x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1994-12-31 | CN¥0.04 | CN¥8.60 | x |
| 1995-12-31 | CN¥0.05 | CN¥8.60 | x |
| 1996-12-31 | CN¥0.22 | CN¥8.60 | x |
| 1997-12-31 | CN¥0.98 | CN¥8.60 | x |
| 1998-12-31 | CN¥1.31 | CN¥8.60 | x |
| 1999-12-31 | CN¥1.57 | CN¥8.60 | x |
| 2000-12-31 | CN¥2.58 | CN¥8.60 | x |
| 2001-12-31 | CN¥2.70 | CN¥8.60 | x |
| 2002-12-31 | CN¥2.78 | CN¥8.60 | x |
| 2003-12-31 | CN¥2.83 | CN¥8.60 | x |
| 2004-12-31 | CN¥2.86 | CN¥8.60 | x |
| 2005-12-31 | CN¥2.54 | CN¥8.60 | x |
| 2006-12-31 | CN¥2.29 | CN¥8.60 | x |
| 2007-12-31 | CN¥2.44 | CN¥8.60 | x |
| 2008-12-31 | CN¥2.27 | CN¥8.60 | x |
| 2009-12-31 | CN¥2.26 | CN¥8.60 | x |
| 2010-12-31 | CN¥2.37 | CN¥8.60 | x |
| 2011-12-31 | CN¥3.00 | CN¥8.60 | x |
| 2012-12-31 | CN¥3.15 | CN¥8.60 | x |
| 2013-12-31 | CN¥3.26 | CN¥8.60 | x |
| 2014-12-31 | CN¥3.34 | CN¥8.60 | x |
| 2015-12-31 | CN¥3.43 | CN¥8.60 | x |
| 2016-12-31 | CN¥3.51 | CN¥8.60 | x |
| 2017-12-31 | CN¥3.14 | CN¥8.60 | x |
| 2018-12-31 | CN¥5.08 | CN¥8.60 | x |
| 2019-12-31 | CN¥4.59 | CN¥8.60 | x |
| 2020-12-31 | CN¥4.61 | CN¥8.60 | x |
| 2021-12-31 | CN¥4.44 | CN¥8.60 | x |
| 2022-12-31 | CN¥4.51 | CN¥8.60 | x |
| 2023-12-31 | CN¥4.20 | CN¥8.60 | x |
| 2024-12-31 | CN¥4.37 | CN¥8.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ginwa Enterprise Group Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.78%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.74%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 1.26x
- Recent ROE (4.78%) is below the historical average (7.62%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1994 | 42.19% | 61.03% | 0.35x | 1.96x | CN¥3.87 Million |
| 1995 | 65.62% | 66.57% | 0.37x | 2.64x | CN¥8.40 Million |
| 1996 | 25.73% | 53.03% | 0.20x | 2.42x | CN¥10.59 Million |
| 1997 | 17.69% | 40.00% | 0.38x | 1.16x | CN¥23.01 Million |
| 1998 | 20.72% | 56.54% | 0.31x | 1.17x | CN¥42.95 Million |
| 1999 | 18.05% | 53.07% | 0.25x | 1.37x | CN¥38.71 Million |
| 2000 | 10.21% | 43.80% | 0.18x | 1.31x | CN¥1.64 Million |
| 2001 | 5.65% | 29.74% | 0.12x | 1.58x | CN¥-35.80 Million |
| 2002 | 3.00% | 14.00% | 0.14x | 1.57x | CN¥-59.53 Million |
| 2003 | 1.65% | 2.70% | 0.36x | 1.69x | CN¥-72.30 Million |
| 2004 | 1.03% | 1.14% | 0.43x | 2.12x | CN¥-78.42 Million |
| 2005 | -12.68% | -12.77% | 0.34x | 2.95x | CN¥-176.06 Million |
| 2006 | -10.81% | -24.57% | 0.16x | 2.74x | CN¥-145.80 Million |
| 2007 | 4.46% | 10.79% | 0.18x | 2.24x | CN¥-41.24 Million |
| 2008 | -7.67% | -10.18% | 0.38x | 1.98x | CN¥-122.54 Million |
| 2009 | -2.12% | -4.40% | 0.24x | 2.00x | CN¥-83.49 Million |
| 2010 | 4.65% | 10.25% | 0.23x | 1.98x | CN¥-38.69 Million |
| 2011 | 18.07% | 43.77% | 0.35x | 1.17x | CN¥73.94 Million |
| 2012 | 4.61% | 9.62% | 0.41x | 1.17x | CN¥-51.78 Million |
| 2013 | 4.57% | 9.68% | 0.40x | 1.19x | CN¥-54.09 Million |
| 2014 | 3.04% | 4.34% | 0.56x | 1.24x | CN¥-71.03 Million |
| 2015 | 2.43% | 3.48% | 0.58x | 1.20x | CN¥-79.13 Million |
| 2016 | 2.55% | 4.09% | 0.46x | 1.35x | CN¥-79.95 Million |
| 2017 | 4.79% | 7.06% | 0.53x | 1.27x | CN¥-58.21 Million |
| 2018 | 2.16% | 5.14% | 0.38x | 1.11x | CN¥-138.80 Million |
| 2019 | 1.51% | 3.43% | 0.38x | 1.15x | CN¥-145.60 Million |
| 2020 | 2.19% | 5.65% | 0.34x | 1.14x | CN¥-134.40 Million |
| 2021 | -1.10% | -3.40% | 0.29x | 1.13x | CN¥-183.78 Million |
| 2022 | 1.99% | 5.78% | 0.29x | 1.17x | CN¥-134.92 Million |
| 2023 | -2.62% | -7.59% | 0.27x | 1.29x | CN¥-206.73 Million |
| 2024 | 4.78% | 12.74% | 0.30x | 1.26x | CN¥-81.44 Million |
Industry Comparison
This section compares Ginwa Enterprise Group Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ginwa Enterprise Group Inc (600080) | CN¥1.58 Billion | 42.19% | 0.24x | $264.23 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |